Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022)
Emergent BioSolutions (EBS) posted quarterly Non-Current Deffered Revenue of $5.9 million for Q1 2022, down 88.76% year-over-year from $52.5 million in Q1 2021, and up 25.53% quarter-over-quarter from $4.7 million in Q4 2021.
Emergent BioSolutions (EBS) Non-Current Deffered Revenue (2010 - 2022) Analysis & Trends
Emergent BioSolutions' Non-Current Deffered Revenue history runs 11 years deep, the most recent figure standing at $5.9 million for Q1 2022.
- In Q1 2022, Non-Current Deffered Revenue fell 88.76% year-over-year to $5.9 million; the TTM figure through Mar 2022 stood at $5.9 million (down 88.76% YoY), while the FY2021 annual figure was $4.7 million, down 91.53% from the prior year.
- Non-Current Deffered Revenue for Q1 2022 stood at $5.9 million, up from $4.7 million in the prior quarter.
- The five-year high for Non-Current Deffered Revenue was $85.6 million in Q4 2019, with the low at $4.7 million in Q4 2021.
- The 5-year median for Non-Current Deffered Revenue is $62.5 million (2018), against an average of $59.0 million.
- The sharpest annual moves came in 2018 and 2021: Non-Current Deffered Revenue soared 327.49% in 2018, then sank 91.53% in 2021.
- Emergent BioSolutions' Non-Current Deffered Revenue stood at $62.5 million in 2018, then soared by 36.96% to $85.6 million in 2019, then slumped by 35.16% to $55.5 million in 2020, then tumbled by 91.53% to $4.7 million in 2021, then climbed by 25.53% to $5.9 million in 2022.
- Business Quant data shows EBS's Non-Current Deffered Revenue at $5.9 million in Q1 2022, $4.7 million in Q4 2021, and $45.3 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | - |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | - |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | - |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | - |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | - |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | - |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | - |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | 5.90 Mn |
| Dec 31, 2021 | 4.70 Mn |
| Sep 30, 2021 | 45.30 Mn |
| Jun 30, 2021 | 48.90 Mn |
| Mar 31, 2021 | 52.50 Mn |
| Dec 31, 2020 | 55.50 Mn |
| Sep 30, 2020 | 60.40 Mn |
| Jun 30, 2020 | 85.30 Mn |
| Mar 31, 2020 | 85.00 Mn |
| Dec 31, 2019 | 85.60 Mn |
| Sep 30, 2019 | 81.60 Mn |
| Jun 30, 2019 | 77.00 Mn |
| Mar 31, 2019 | 64.70 Mn |
| Dec 31, 2018 | 62.50 Mn |
| Sep 30, 2018 | 65.34 Mn |
| Jun 30, 2018 | 63.26 Mn |
| Mar 31, 2018 | 59.37 Mn |
| Dec 31, 2017 | 17.30 Mn |
| Sep 30, 2017 | 24.97 Mn |
| Jun 30, 2017 | 17.09 Mn |